Aurobindo Pharma, Sun Pharma recall Rasagiline Tablets, Cequa from US market
The US health regulator stated that Aurobindo Pharma is recalling 9,890 bottles of Rasagiline Tablets, a medication indicated for the treatment of Parkinson's disease, from the US.
New Delhi: Leading drug makers Sun Pharmaceutical Industries and Aurobindo Pharma are recalling products from the US market due to manufacturing issues, according to the US Food & Drug Administration.
As per the latest Enforcement Report issued by the American health regulator, a US-based subsidiary of Mumbai-based Sun Pharma is recalling 69,707 cartons of Cequa (cyclosporine ophthalmic solution) from the US market.
The medication is used for the treatment of dry eyes.
New Jersey-based Sun Pharmaceutical Industries Inc is recalling the product for being "Subpotent'', USFDA stated.
The company initiated the nationwide (US) Class III recall on September 7 this year.
As per the USFDA, a Class III recall is initiated in a "situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences".
The US health regulator stated that Aurobindo Pharma is recalling 9,890 bottles of Rasagiline Tablets, a medication indicated for the treatment of Parkinson's disease, from the US.
New Jersey-based Aurobindo Pharma USA Inc, a unit of the Hyderabad-based drug major, is recalling the affected lot due to "Failed dissolution specifications", the USFDA noted.
Read also: 3 baby formula makers get USFDA warning letter to correct manufacturing process controls
The company initiated the Class II recall in the US on August 2 this year.
As per the USFDA, a class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.
Read also: Popular antacid Digene gel receives warning alert from DCGI, Abbott initiates recall
The Indian pharmaceutical industry is the third largest in the world by volume with a current market size of around USD 50 billion.
India exported pharmaceuticals worth Rs 1,75,040 crore in 2021-22, including bulk drugs/drug intermediates.
Read also: USFDA accepts Sun Pharma NDA for alopecia areata drug Deuruxolitinib
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.